Phenyl sulfate, indoxyl sulfate and p-cresyl sulfate decrease glutathione level to render cells vulnerable to oxidative stress in renal tubular cells

PLoS ONE

Volumn 13, Issue 2, 2018, Pages

  Edamatsu, Takeo ^a   Fujieda, Ayako ^a   Itoh, Yoshiharu ^a  

^a KUREHA CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 CRESYLSULFATE; BUTHIONINE SULFOXIMINE; GLUTATHIONE; HYDROGEN PEROXIDE; INDICAN; PHENYLSULFATE; SULFUR DERIVATIVE; UNCLASSIFIED DRUG; 4-CRESOL SULFATE; ANTIMETABOLITE; CRESOL; SULFATE;

ANIMAL CELL; ARTICLE; CELL DAMAGE; CELL DEATH; CELL STRESS; CONTROLLED STUDY; HEMODIALYSIS PATIENT; KIDNEY TUBULE CELL; NONHUMAN; OXIDATIVE STRESS; PIG; PROTEIN BINDING; PROTEIN FUNCTION; UREMIA; ANIMAL; APOPTOSIS; CELL LINE; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; KIDNEY TUBULE; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTIMETABOLITES; APOPTOSIS; BUTHIONINE SULFOXIMINE; CELL LINE; CELL SURVIVAL; CRESOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTATHIONE; HYDROGEN PEROXIDE; INDICAN; KIDNEY TUBULES; OXIDATIVE STRESS; SULFURIC ACID ESTERS; SUS SCROFA;

EID: 85042503520     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0193342     Document Type: Article

References (40)

1. Massy ZA, Stenvinkel P, Drueke TB. The role of oxidative stress in chronic kidney disease. Semin Dial. 2009; 22(4): 405–408. https://doi.org/10.1111/j.1525-139X.2009.00590.x PMID: 19708991
2. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimbürger O, Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol. 2008; 3(2): 505–521. https://doi.org/10.2215/CJN.03670807PMID: 18184879
3. Del Vecchio L, Locatelli F, Carini M. What we know about oxidative stress in patients with chronic kidney disease on dialysis—clinical effects, potential treatment, and prevention. Semin Dial. 2011; 24(1): 56–64. https://doi.org/10.1111/j.1525-139X.2010.00819.x PMID: 21299632
4. United States Renal Data System: 2016 Annual Data Report Volume 2, Chapter 9: Cardiovascular Disease in Patients with ESRD.
5. Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, et al. Normal and patho-logic concentrations of uremic toxins. J Am Soc Nephrol. 2012; 23(7): 1258–1270. https://doi.org/10.1681/ASN.2011121175 PMID: 22626821
6. Vanholder R, De Smet R, Lameire N. Protein-bound uremic solutes: the forgotten toxins. Kidney Int Suppl. 2001; 78: S266–270. https://doi.org/10.1046/j.1523-1755.2001.59780266.x PMID: 11169024
7. Leong SC, Sirich TL. Indoxyl Sulfate-Review of Toxicity and Therapeutic Strategies. Toxins (Basel). 2016; 8(12): E358.
8. Hung SC, Kuo KL, Wu CC, Tarng DC. Indoxyl Sulfate: A Novel Cardiovascular Risk Factor in Chronic Kidney Disease. J Am Heart Assoc. 2017; 6(2): e005022. https://doi.org/10.1161/JAHA.116.005022 PMID: 28174171
9. Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol. 2009; 4(10): 1551–1558. https://doi.org/10.2215/CJN.03980609 PMID: 19696217
10. Dou L, Jourde-Chiche N, Faure V, Cerini C, Berland Y, Dignat-George F, et al. The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J Thromb Haemost. 2007; 5(6): 1302–1308. https://doi.org/10.1111/j.1538-7836.2007.02540.x PMID: 17403109
11. Muteliefu G, Enomoto A, Jiang P, Takahashi M, Niwa T. Indoxyl sulphate induces oxidative stress and the expression of osteoblast-specific proteins in vascular smooth muscle cells. Nephrol Dial Transplant. 2009; 24(7): 2051–2058. https://doi.org/10.1093/ndt/gfn757 PMID: 19164326
12. Ito S, Higuchi Y, Yagi Y, Nishijima F, Yamato H, Ishii H, et al. Reduction of indoxyl sulfate by AST-120 attenuates monocyte inflammation related to chronic kidney disease. J Leukoc Biol. 2013; 93(6): 837–845. https://doi.org/10.1189/jlb.0112023 PMID: 23362306
13. Motojima M, Hosokawa A, Yamato H, Muraki T, Yoshioka T. Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells. Kidney Int. 2003; 63(5): 1671–1680. https://doi.org/10.1046/j.1523-1755.2003.00906.x PMID: 12675842
14. Watanabe H, Miyamoto Y, Honda D, Tanaka H, Wu Q, Endo M, et al. p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase. Kidney Int. 2013; 83 (4): 582–592. https://doi.org/10.1038/ki.2012.448 PMID: 23325087
15. Kikuchi K, Itoh Y, Tateoka R, Ezawa A, Murakami K, Niwa T. Metabolomic search for uremic toxins as indicators of the effect of an oral sorbent AST-120 by liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2010; 878(29): 2997–3002. https://doi.org/10.1016/j.jchromb.2010.09.006 PMID: 20870466
16. Itoh Y, Ezawa A, Kikuchi K, Tsuruta Y, Niwa T. Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production. Anal Bioanal Chem. 2012; 403(7): 1841–1850. https://doi.org/10.1007/s00216-012-5929-3PMID: 22447217
17. Edamatsu T, Fujieda A, Ezawa A, Itoh Y. Classification of five uremic solutes according to their effects on renal tubular cells. Int J Nephrol 2014; 2014: 512178. https://doi.org/10.1155/2014/512178 PMID: 25431671
18. Griffith OW, Meister A. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem. 1979; 254(16): 7558–7560. PMID: 38242
19. Boelaert J, Lynen F, Glorieux G, Eloot S, Van Landschoot M, Waterloos MA, et al. A novel UPLC-MS-MS method for simultaneous determination of seven uremic retention toxins with cardiovascular relevance in chronic kidney disease patients. Anal Bioanal Chem 2013; 405(6): 1937–1947. https://doi.org/10.1007/s00216-012-6636-9 PMID: 23307120
20. Sato E, Mori T, Mishima E, Suzuki A, Sugawara S, Kurasawa N, et al. Metabolic alterations by indoxyl sulfate in skeletal muscle induce uremic sarcopenia in chronic kidney disease. Sci Rep. 2016; 6: 36618. https://doi.org/10.1038/srep36618 PMID: 27830716
21. Tucker PS, Dalbo VJ, Han T, Kingsley MI. Clinical and research markers of oxidative stress in chronic kidney disease. Biomarkers. 2013; 18(2): 103–115. https://doi.org/10.3109/1354750X.2012.749302PMID: 23339563
22. Annuk M, Zilmer M, Lind L, Linde T, Fellström B. Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol. 2001; 12(12): 2747–2752. PMID: 11729244
23. Galli F, Piroddi M, Bartolini D, Ciffolilli S, Buoncristiani E, Ricci G, et al. Blood thiol status and erythrocyte glutathione-S-transferase in chronic kidney disease patients on treatment with frequent (daily) hemodialysis. Free Radic Res. 2014; 48(3): 273–281. https://doi.org/10.3109/10715762.2013.861901PMID: 24192047
24. Calderón-Salinas JV, Muñoz-Reyes EG, Guerrero-Romero JF, Rodríguez-Morán M, Bracho-Riquelme RL, Carrera-Gracia MA, et al. Eryptosis and oxidative damage in type 2 diabetic mellitus patients with chronic kidney disease. Mol Cell Biochem. 2011; 357(1–2): 171–179. https://doi.org/10.1007/s11010-011-0887-1 PMID: 21625956
25. Kumawat M, Sharma TK, Singh I, Singh N, Ghalaut VS, Vardey SK, et al. Antioxidant Enzymes and Lipid Peroxidation in Type 2 Diabetes Mellitus Patients with and without Nephropathy. N Am J Med Sci. 2013; 5(3): 213–219. https://doi.org/10.4103/1947-2714.109193 PMID: 23626958
26. Gupta S, Gambhir JK, Kalra O, Gautam A, Shukla K, Mehndiratta M, et al. Association of biomarkers of inflammation and oxidative stress with the risk of chronic kidney disease in Type 2 diabetes mellitus in North Indian population. J Diabetes Complications. 2013; 27(6): 548–552. https://doi.org/10.1016/j.jdiacomp.2013.07.005 PMID: 24012111
27. Kir HM, Dillioglugil MO, Tugay M, Eraldemir C, Ozdoğan HK. Effects of vitamins E, A and D on MDA, GSH, NO levels and SOD activities in 5/6 nephrectomized rats. Am J Nephrol. 2005; 25(5): 441–446. https://doi.org/10.1159/000087825 PMID: 16118481
28. Kasimay O, Sener G, Cakir B, Yüksel M, Cetinel S, Contuk G, et al. Estrogen protects against oxidative multiorgan damage in rats with chronic renal failure. Ren Fail. 2009; 31(8): 711–725. https://doi.org/10.3109/08860220903134563 PMID: 19814639
29. Kadowaki D, Sumikawa S, Arimizu K, Taguchi K, Kitamura K, Ishitsuka Y, et al. Effect of acetaminophen on the progression of renal damage in adenine induced renal failure model rats. Life Sci. 2012; 91 (25–26): 1304–1308. https://doi.org/10.1016/j.lfs.2012.09.018 PMID: 23069583
30. Owada S, Tsukamoto T, Toyama K, Komurai M, Ominato M, Ishii Y, et al. Erythrocyte redox state in hemodialyzed patients: glutathione and glutathione-related enzymes. J Artif Organs. 2001; 4: 8–18.
31. Santangelo F, Witko-Sarsat V, Drüeke T, Descamps-Latscha B. Restoring glutathione as a therapeutic strategy in chronic kidney disease. Nephrol Dial Transplant. 2004; 19(8): 1951–1955. https://doi.org/10.1093/ndt/gfh266 PMID: 15252168
32. Laouari D, Yang R, Veau C, Blanke I, Friedlander G. Two apical multidrug transporters, P-gp and MRP2, are differently altered in chronic renal failure. Am J Physiol Renal Physiol. 2001; 280(4): F636–645. https://doi.org/10.1152/ajprenal.2001.280.4.F636 PMID: 11249855
33. Calunga JL, Zamora ZB, Borrego A, Río Sd, Barber E, Menéndez S, et al. Ozone therapy on rats submitted to subtotal nephrectomy: role of antioxidant system. Mediators Inflamm. 2005; 2005(4): 221–227. https://doi.org/10.1155/MI.2005.221 PMID: 16192672
34. Yu M, Kim YJ, Kang DH. Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clin J Am Soc Nephrol. 2011; 6(1): 30–39. https://doi.org/10.2215/CJN.05340610 PMID: 20876676
35. Mimić-Oka J, Simić T, Djukanović L, Reljić Z, Davicević Z. Alteration in plasma antioxidant capacity in various degrees of chronic renal failure. Clin Nephrol. 1999; 51(4): 233–241. PMID: 10230556
36. Moningka NC, Tsarova T, Sasser JM, Baylis C. Protective actions of nebivolol on chronic nitric oxide synthase inhibition-induced hypertension and chronic kidney disease in the rat: a comparison with angiotensin II receptor blockade. Nephrol Dial Transplant. 2012; 27(3): 913–920. https://doi.org/10.1093/ndt/gfr449 PMID: 21856762
37. Kuczmarski JM, Martens CR, Lennon-Edwards SL, Edwards DG. Cardiac function and tolerance to ischemia-reperfusion injury in chronic kidney disease. Nephrol Dial Transplant. 2014; 29(8): 1514–1524. https://doi.org/10.1093/ndt/gft336 PMID: 24151020
38. Moh A, Sakata N, Takebayashi S, Tateishi K, Nagai R, Horiuchi S, et al. Increased production of urea hydrogen peroxide from Maillard reaction and a UHP-Fenton pathway related to glycoxidation damage in chronic renal failure. J Am Soc Nephrol. 2004; 15(4): 1077–1085. PMID: 15034112
39. Forman HJ, Bernardo A, Davies KJ. What is the concentration of hydrogen peroxide in blood and plasma? Arch Biochem Biophys. 2016; 603: 48–53. https://doi.org/10.1016/j.abb.2016.05.005 PMID: 27173735
40. Vanholder R, Schepers E, Pletinck A, Nagler EV, Glorieux G. The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. J Am Soc Nephrol. 2014; 25(9): 1897–1907. https://doi.org/10.1681/ASN.2013101062 PMID: 24812165